Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Areal-world retrospective study reports significantly longer radiological progression-free survival (rPFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide vs abiraterone acetate after previous docetaxel therapy.
The width of the spared neurovascular bundle (NVB) is an important indicator of postoperative sexual function after robot-assisted laparoscopic prostatectomy for prostate cancer, a recent study has found. These findings point to NVB as an easy intraoperative marker for assessing postoperative outcomes.
Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.
In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.
Use of atorvastatin for a year appears to confer no benefit for the risk of disease recurrence among prostate cancer patients with high-risk pathologic features who have undergone radical prostatectomy, a study has found.
Older men with Gleason grade group (GG) 1 prostate cancer are more likely to have adverse pathology at radical prostatectomy after initially being managed with active surveillance (AS), a study reports. As such, closer monitoring and additional testing are required to improve their risk stratification.
The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.
In prostate cancer (PC) patients undergoing hormone therapy, the development of lifestyle-related disorders, particularly diabetes mellitus (DM), predicts an earlier progression to castration-resistant PC (CRPC) and poor prognosis, a recent study has found.